In this article we provide an in-depth analysis of the Bank of England’s decision to reduce the Official Bank Rate by 0.25%. 

Why have obesity drugs captivated both the medical community and investors’ attention over the last two years?

Here we discuss the Magnificent 7, why they have performed so well, and why we don’t own all these stocks at such high concentration in CCLA equity portfolios.

CCLA reacts to findings by Broadstone independent charity consultancy firm. 

Here we discuss why we support mandatory scope 3 disclosure, why it matters and how companies are progressing. 

In sustainable investment circles it has been hard to escape the news that the world's top five money managers are quitting Climate Action 100+. What does this mean for investors and the industry?

With biodiversity loss rising rapidly up the scale of investor concerns, this article explores what is being done on a global policy basis, the risks to investors and how we can engage with companies.

In our latest article, we share why we think 2024 is best suited to quality growth stocks.

CCLA's first benchmark on modern slavery seeks to create an objective assessment of corporate modern slavery performance. Findings show that while companies have policies in place, companies need to focus on implementing these policies and taking action when they find modern slavery.

This paper looks at whether the integration of artificial intelligence and other new technologies could revolutionise the way investors and businesses address modern slavery risks.